Bloom Burton

AceAge is a healthcare technology company, creating intuitive products to ease the aging process and improve health outcomes. AceAge is the company behind the next innovation in healthcare technology. Its upcoming product is a home health appliance designed to help people take their medication properly. Karie is a personal health companion that organizes, schedules, and dispenses pills with easy one-button control. The CEO of AceAge, Spencer Waugh, created Karie to increase the health and safety of medical patients, and as a way to minimize the negative consequences of missed medications or general failure to adhere to medication directions. The success of medicine is dependent on the patient’s compliance with the medical directions that accompany it, making it an integral part of healthcare. The total direct and indirect costs of nonadherence in the US annually is $290 billion. By making daily medicine routines completely automated, Karie removes the chance of human error. Karie uses common multi-dose pouch packaging that can be pre-set by pharmacists. Doses are scheduled, delivered and monitored for the user. Karie is easy to use, enables greater patient autonomy and ensures better healthcare through a highly coordinated program.

Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.

Antibe Therapeutics develops novel anti-inflammatory drugs that are improved versions of existing drugs. They focus on diseases characterized by inflammation, pain, and/or vascular dysfunction. Their drug design approach is to create new drugs by improving existing, proven drugs. The company's technology platform enables us to chemically link an existing drug to a hydrogen sulfide-releasing moeity. Hydrogen sulfide (H2S) is one of several so-called gaseous mediators. Gaseous mediators are naturally occurring substances found in the human body. Acting as neuromodulators, immunomodulators, and vasodilators, gaseous mediators such as H2S regulate fundamental cellular processes. Antibe believes that H2S has tremendous therapeutic potential. Antibe’s R&D is guided by a leading team of pharmaceutical researchers and advisors. The team includes a Nobel Prize winner, highly successful entrepreneurs, and senior scientists affiliated with major research institutions worldwide.

Appili Therapeutics is an anti-infective pharmaceutical development company. Our approach lies in matching unmet medical needs with opportunities for more effective solutions that range from improvements in established therapies to entirely new classes of anti-infectives.

HLS is dedicated to the stewardship of branded pharmaceuticals through their life cycles post - exclusivity. HLS ensures the availability of treatments critical to patients and their caregivers with the brand names they trust.

Hamilton Thorne, Inc. is a leading provider of advanced laser systems and instruments for in-vitro cell applications in the regenerative medicine research and fertility clinic markets. Hamilton Thorne's ZILOS-tk and XYClone laser systems attach to standard inverted microscopes and operate as robotic micro-surgeons, reducing time and increasing efficiency in key stem cell, embryo and living cell procedures. Hamilton Thorne's CASA systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the animal, human infertility and reproductive toxicology fields. The Company's novel laser systems are rapidly emerging as the dominant products to facilitate precise micro-surgical procedures with stem cells and other living cells in the laboratory. Specific applications include the reduction from nine months to six weeks to develop transgenic animal models, dramatic reductions in cell damage during micro-surgical procedures and 50% higher yields for many cell procedures. The Company sells its products to pharmaceutical companies, biotechnology companies, fertility clinics, university research centers and other commercial and academic research establishments worldwide. Hamilton Thorne's current customers include some of the leading research labs in the world, including Harvard University, MIT, Yale, Dupont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University and Cambridge.

BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTA™, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™. KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ pre-clinical studies for the treatment of sHUS are currently underway. BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

Knight Therapeutics is a specialty pharmaceutical company that focuses on acquiring, in-licensing, out-licensing, marketing, and distributing innovative prescription pharmaceuticals.

Newtopia is a personalized health company - leveraging personal genetics and the latest engagement science - to solve a big problem: our unhealthy lifestyles are killing us, and costing corporations a fortune. Whether obesity, chronic disease, or aging, these all have roots in our lifestyle behaviors and there is no improvement in sight. It’s an absolutely massive market in a perfect storm for disruption - both individuals and corporations are looking - and willing to spend - on solutions but existing providers are failing to provide sustainable solutions. The result - our lifestyles are having giant economic and social consequences. Newtopia’s patented solution to the problem is the invention of a unique health engagement platform. What is a health engagement platform? We inspire people to make the right lifestyle decisions to stay healthy. With a proven $2-$3 per day model, an 80% success rate with beta clients, and early success selling and delivering results to large corporations and insurers, Newtopia is the perfect B2B partner. Newtopia's opportunity to scale comes through partnering with insurers, self-insured employers and brands to deliver sustainable health outcomes and a meaningful ROI.

Noden Pharma is a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a range of therapeutic areas. Noden Pharma DAC holds exclusive worldwide rights to manufacture, market and sell Tekturna® and Tekturna HCT® (or Rasilez® and Rasilez HTC® outside of the United States), which contain aliskiren, a direct renin inhibitor, for the treatment of hypertension.

Knight Therapeutics is a specialty pharmaceutical company that focuses on acquiring, in-licensing, out-licensing, marketing, and distributing innovative prescription pharmaceuticals.

Hamilton Thorne, Inc. is a leading provider of advanced laser systems and instruments for in-vitro cell applications in the regenerative medicine research and fertility clinic markets. Hamilton Thorne's ZILOS-tk and XYClone laser systems attach to standard inverted microscopes and operate as robotic micro-surgeons, reducing time and increasing efficiency in key stem cell, embryo and living cell procedures. Hamilton Thorne's CASA systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the animal, human infertility and reproductive toxicology fields. The Company's novel laser systems are rapidly emerging as the dominant products to facilitate precise micro-surgical procedures with stem cells and other living cells in the laboratory. Specific applications include the reduction from nine months to six weeks to develop transgenic animal models, dramatic reductions in cell damage during micro-surgical procedures and 50% higher yields for many cell procedures. The Company sells its products to pharmaceutical companies, biotechnology companies, fertility clinics, university research centers and other commercial and academic research establishments worldwide. Hamilton Thorne's current customers include some of the leading research labs in the world, including Harvard University, MIT, Yale, Dupont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University and Cambridge.

Profound Medical team is committed to creating the powerful combination of real-time MR guidance as the imaging platform and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patients and clinicians in many anatomies and disease states, including prostate cancer, uterine fibroids, and bone metastases. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives.

Knight Therapeutics is a specialty pharmaceutical company that focuses on acquiring, in-licensing, out-licensing, marketing, and distributing innovative prescription pharmaceuticals.

Newtopia is a personalized health company - leveraging personal genetics and the latest engagement science - to solve a big problem: our unhealthy lifestyles are killing us, and costing corporations a fortune. Whether obesity, chronic disease, or aging, these all have roots in our lifestyle behaviors and there is no improvement in sight. It’s an absolutely massive market in a perfect storm for disruption - both individuals and corporations are looking - and willing to spend - on solutions but existing providers are failing to provide sustainable solutions. The result - our lifestyles are having giant economic and social consequences. Newtopia’s patented solution to the problem is the invention of a unique health engagement platform. What is a health engagement platform? We inspire people to make the right lifestyle decisions to stay healthy. With a proven $2-$3 per day model, an 80% success rate with beta clients, and early success selling and delivering results to large corporations and insurers, Newtopia is the perfect B2B partner. Newtopia's opportunity to scale comes through partnering with insurers, self-insured employers and brands to deliver sustainable health outcomes and a meaningful ROI.

Knight Therapeutics is a specialty pharmaceutical company that focuses on acquiring, in-licensing, out-licensing, marketing, and distributing innovative prescription pharmaceuticals.

Medicago Inc., a biotechnology company, focuses on the research, development, production, and commercialization of vaccines in Canada. The company develops its vaccines based on its proprietary technologies, including the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidate includes H5N1 pandemic influenza VLP vaccine, which has completed a Phase I human clinical trial. The company is also developing H1N1 VLP vaccine for Influenza A/California/04/09 virus; and seasonal influenza vaccines. Medicago Inc. has collaboration agreements with Viridis S.A.; Genopole biopark to manufacture pandemic and seasonal influenza vaccines; and Philip Morris International to produce a therapeutic protein with a humancompatible glycosylation pattern. The company was incorporated in 1997 and is headquartered in Quebec City, Canada.

Oncolytics Biotech focuses the research and development efforts on the development of REOLYSIN, the cancer therapeutic. The product for human use, REOLYSIN is developed from the reovirus. The virus has been demonstrated to replicate in the tumour cells bearing an activated Ras pathway. The Ras protein is a regulator of cell growth and differentiation. It transmits signals from the cell's surface, through growth factor receptors, to downstream elements, which are in turn relayed to the nucleus. The transmission of signals from the cell surface to the cell's nucleus is referred to as the signal transduction. The wholly owned subsidiaries of the company include Oncolytics Biotech (Barbados) Inc. and Oncoltics Biotech (US) Inc. In April 2009, the Company completed the acquisition of an inactive private company. Oncolytics Biotech was founded on 1988 and is based in Calgary, Alberta, Canada.